Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B02BDOrphan MedicineConditional Approval

Hemgenix(Etranacogene dezaparvovec)

Hemophilia B

Marketing Authorisation Holder: CSL Behring GmbH

EMA Authorisation: 20/02/2023

INN: etranacogene dezaparvovec

Indication

Treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Hemgenix — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.